Abstract
Background: Asthma guidelines vary in their recommendations for the initial dose of inhaled corticosteroid (ICS) in asthma. A systematic review of the literature was conducted to establish the optimal starting dose of ICS for asthma in adults.
Methods: Randomised controlled trials comparing two doses of the same ICS in adults with asthma and no concomitant inhaled or oral corticosteroid were assessed. Included trials were analysed according to the following ICS dose comparisons: high (⩾800 µg/day beclomethasone (BDP)) versus moderate (400<800 µg/day BDP) (n = 7); moderate versus low (<400 µg/day BDP) (n = 6); step down versus constant dose (n = 4).
Results: Fourteen publications describing 13 trials were included in the review. Studies (n = 4) that compared a step down approach with a constant moderate/low dose of ICS found no difference in lung function, symptoms, or rescue medications between the two treatment approaches (p>0.05). There was no difference in the change in morning peak flow after treatment with high compared with moderate dose ICS. When compared with low dose ICS, moderate dose ICS significantly improved morning peak flow (change from baseline WMD 11.14 l/min, 95% CI 1.34 to 20.93) and nocturnal symptoms (SMD –0.29, 95% CI –0.53 to –0.06).
Conclusions: For patients with asthma who require ICS, starting with a moderate dose is equivalent to starting with a high dose and stepping down. The small non-significant benefits of starting with a high ICS dose are not of sufficient clinical benefit to warrant its use. Initial moderate ICS doses appear to be more effective than an initial low ICS dose.
Full Text
The Full Text of this article is available as a PDF (105.8 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barnes P. J., Pedersen S., Busse W. W. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med. 1998 Mar;157(3 Pt 2):S1–53. doi: 10.1164/ajrccm.157.3.157315. [DOI] [PubMed] [Google Scholar]
- Black P. N., Lawrence B. J., Goh K. H., Barry M. S. Differences in the potencies of inhaled steroids are not reflected in the doses prescribed in primary care in New Zealand. Eur J Clin Pharmacol. 2000 Aug;56(5):431–435. doi: 10.1007/s002280000140. [DOI] [PubMed] [Google Scholar]
- Campbell L. M., Gooding T. N., Aitchison W. R., Smith N., Powell J. A. Initial loading (400 micrograms twice daily) versus static (400 micrograms nocte) dose budesonide for asthma management. PLAN Research Group. Int J Clin Pract. 1998 Sep;52(6):361-8, 370. [PubMed] [Google Scholar]
- Chanez P., Karlstrom R., Godard P. High or standard initial dose of budesonide to control mild-to-moderate asthma? Eur Respir J. 2001 May;17(5):856–862. doi: 10.1183/09031936.01.17508560. [DOI] [PubMed] [Google Scholar]
- Gauderman W. James, Avol Edward, Gilliland Frank, Vora Hita, Thomas Duncan, Berhane Kiros, McConnell Rob, Kuenzli Nino, Lurmann Fred, Rappaport Edward. The effect of air pollution on lung development from 10 to 18 years of age. N Engl J Med. 2004 Sep 9;351(11):1057–1067. doi: 10.1056/NEJMoa040610. [DOI] [PubMed] [Google Scholar]
- Holt S., Suder A., Weatherall M., Cheng S., Shirtcliffe P., Beasley R. Dose-response relation of inhaled fluticasone propionate in adolescents and adults with asthma: meta-analysis. BMJ. 2001 Aug 4;323(7307):253–256. doi: 10.1136/bmj.323.7307.253. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jadad A. R., Moore R. A., Carroll D., Jenkinson C., Reynolds D. J., Gavaghan D. J., McQuay H. J. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996 Feb;17(1):1–12. doi: 10.1016/0197-2456(95)00134-4. [DOI] [PubMed] [Google Scholar]
- Jatakanon A., Kharitonov S., Lim S., Barnes P. J. Effect of differing doses of inhaled budesonide on markers of airway inflammation in patients with mild asthma. Thorax. 1999 Feb;54(2):108–114. doi: 10.1136/thx.54.2.108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Lorentzson S., Boe J., Eriksson G., Persson G. Use of inhaled corticosteroids in patients with mild asthma. Thorax. 1990 Oct;45(10):733–735. doi: 10.1136/thx.45.10.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Majima T., Katoh H., Yoshida N., Akiyama Y., Hashimoto N., Yamaguchi M., Horie T. [Effects of high doses of beclomethasone dipropionate in bronchial asthma]. Arerugi. 1993 Apr;42(4):534–540. [PubMed] [Google Scholar]
- Miyamoto T., Takahashi T., Nakajima S., Makino S., Yamakido M., Mano K., Nakashima M., Tollemar U., Selroos O. A double-blind, placebo-controlled dose-response study with budesonide Turbuhaler in Japanese asthma patients. Japanese Pulmicort Turbuhaler study group. Respirology. 2000 Sep;5(3):247–256. doi: 10.1046/j.1440-1843.2000.00256.x. [DOI] [PubMed] [Google Scholar]
- Noonan M. J., Chervinsky P., Wolfe J., Liddle R., Kellerman D. J., Crescenzi K. L. Dose-related response to inhaled fluticasone propionate in patients with methacholine-induced bronchial hyperresponsiveness: a double-blind, placebo-controlled study. J Asthma. 1998;35(2):153–164. doi: 10.3109/02770909809068203. [DOI] [PubMed] [Google Scholar]
- O'Byrne P. M., Barnes P. J., Rodriguez-Roisin R., Runnerstrom E., Sandstrom T., Svensson K., Tattersfield A. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001 Oct 15;164(8 Pt 1):1392–1397. doi: 10.1164/ajrccm.164.8.2104102. [DOI] [PubMed] [Google Scholar]
- Pedersen B., Dahl R., Karlström R., Peterson C. G., Venge P. Eosinophil and neutrophil activity in asthma in a one-year trial with inhaled budesonide. The impact of smoking. Am J Respir Crit Care Med. 1996 May;153(5):1519–1529. doi: 10.1164/ajrccm.153.5.8630596. [DOI] [PubMed] [Google Scholar]
- Powell Heather, Gibson Peter G. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust. 2003 Mar 3;178(5):223–225. doi: 10.5694/j.1326-5377.2003.tb05167.x. [DOI] [PubMed] [Google Scholar]
- Sheffer A. L., LaForce C., Chervinsky P., Pearlman D., Schaberg A. Fluticasone propionate aerosol: efficacy in patients with mild to moderate asthma. Fluticasone Propionate Asthma Study Group. J Fam Pract. 1996 Apr;42(4):369–375. [PubMed] [Google Scholar]
- Suissa S., Ernst P. Inhaled corticosteroids: impact on asthma morbidity and mortality. J Allergy Clin Immunol. 2001 Jun;107(6):937–944. doi: 10.1067/mai.2001.115653. [DOI] [PubMed] [Google Scholar]
- Todd G. R. G., Acerini C. L., Buck J. J., Murphy N. P., Ross-Russell R., Warner J. T., McCance D. R. Acute adrenal crisis in asthmatics treated with high-dose fluticasone propionate. Eur Respir J. 2002 Jun;19(6):1207–1209. doi: 10.1183/09031936.02.00274402. [DOI] [PubMed] [Google Scholar]
- Wasserman S. I., Gross G. N., Schoenwetter W. F., Munk Z. M., Kral K. M., Schaberg A., Kellerman D. J. A 12-week dose-ranging study of fluticasone propionate powder in the treatment of asthma. J Asthma. 1996;33(4):265–274. doi: 10.3109/02770909609055367. [DOI] [PubMed] [Google Scholar]
- van der Molen T., Meyboom-de Jong B., Mulder H. H., Postma D. S. Starting with a higher dose of inhaled corticosteroids in primary care asthma treatment. Am J Respir Crit Care Med. 1998 Jul;158(1):121–125. doi: 10.1164/ajrccm.158.1.9707035. [DOI] [PubMed] [Google Scholar]